Lake Street Advisors Group LLC Purchases New Holdings in Novartis AG (NVS)

Lake Street Advisors Group LLC purchased a new stake in Novartis AG (NYSE:NVS) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 8,989 shares of the company’s stock, valued at approximately $755,000.

Several other large investors have also added to or reduced their stakes in the business. Garland Capital Management Inc. raised its holdings in shares of Novartis by 1.0% in the 4th quarter. Garland Capital Management Inc. now owns 52,233 shares of the company’s stock valued at $4,385,000 after acquiring an additional 535 shares in the last quarter. Tradition Capital Management LLC raised its holdings in shares of Novartis by 0.9% in the 4th quarter. Tradition Capital Management LLC now owns 69,381 shares of the company’s stock valued at $5,825,000 after acquiring an additional 652 shares in the last quarter. Commerce Bank raised its holdings in shares of Novartis by 2.4% in the 4th quarter. Commerce Bank now owns 28,004 shares of the company’s stock valued at $2,352,000 after acquiring an additional 664 shares in the last quarter. West Oak Capital LLC raised its holdings in shares of Novartis by 4.4% in the 4th quarter. West Oak Capital LLC now owns 15,860 shares of the company’s stock valued at $1,332,000 after acquiring an additional 665 shares in the last quarter. Finally, Lenox Wealth Management Inc. raised its holdings in shares of Novartis by 6.9% in the 3rd quarter. Lenox Wealth Management Inc. now owns 10,585 shares of the company’s stock valued at $908,000 after acquiring an additional 683 shares in the last quarter. 10.76% of the stock is currently owned by hedge funds and other institutional investors.

How to Become a New Pot Stock Millionaire

Novartis AG (NYSE NVS) opened at $81.23 on Tuesday. The firm has a market capitalization of $190,170.44, a PE ratio of 24.99, a P/E/G ratio of 1.91 and a beta of 0.78. The company has a current ratio of 1.21, a quick ratio of 0.91 and a debt-to-equity ratio of 0.31. Novartis AG has a 1-year low of $72.67 and a 1-year high of $94.19.

Novartis (NYSE:NVS) last announced its quarterly earnings data on Wednesday, January 24th. The company reported $1.20 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.16 by $0.04. Novartis had a return on equity of 16.03% and a net margin of 15.69%. The company had revenue of $12.92 billion for the quarter, compared to analysts’ expectations of $12.65 billion. During the same period last year, the firm posted $1.14 EPS. Novartis’s revenue for the quarter was up 4.8% compared to the same quarter last year. research analysts anticipate that Novartis AG will post 5.36 earnings per share for the current year.

Several analysts have weighed in on NVS shares. Nord/LB reaffirmed a “neutral” rating on shares of Novartis in a report on Tuesday, January 2nd. Bank of America cut Novartis from a “neutral” rating to an “underperform” rating in a report on Wednesday, December 6th. Zacks Investment Research cut Novartis from a “hold” rating to a “sell” rating in a report on Tuesday, January 2nd. UBS reissued a “neutral” rating on shares of Novartis in a report on Monday, January 15th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novartis in a report on Thursday, January 18th. Four equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $87.51.

ILLEGAL ACTIVITY NOTICE: This article was first published by Stock Observer and is owned by of Stock Observer. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at https://www.thestockobserver.com/2018/03/20/lake-street-advisors-group-llc-purchases-new-holdings-in-novartis-ag-nvs.html.

Novartis Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply